Dec 10, 2019 7:30am EST ProMIS Neurosciences’ Alzheimer’s disease program takes on renewed significance following positive aducanumab news
Dec 05, 2019 12:50pm EST Aducanumab is good; next generation Alzheimer’s disease therapies will be better
Nov 07, 2019 7:30am EST ProMIS Neurosciences Outlines Best-in-class Approach to Amyloid-beta-targeting Drug Candidates for Alzheimer’s Disease
Nov 07, 2019 7:30am EST ProMIS Neurosciences outlines best-in-class approach to amyloid-beta-targeting drug candidates for Alzheimer's disease
Oct 24, 2019 3:00am EDT ProMIS Neurosciences issues Chairman's update memorandum and white paper on Alzheimer's disease
Oct 23, 2019 9:49am EDT ProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-43
Oct 17, 2019 7:30am EDT ProMIS Neurosciences advances Alzheimer’s disease program targeting neurotoxic forms of tau